Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles

Journal of Viral Hepatitis

Volumn 16, Issue 12, 2009, Pages 876-882

  You, Hong ^a   Ma, Hong ^a   Liu, Tianhui ^a   Cong, Min ^a   Wang, Ping ^a   Ou, Xiaojuan ^a   Wang, Xiaoming ^a   Ren, Jiangbo ^a   Li, Hongyi ^a   Wang, Baoen ^a   Jia, Jidong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; HBeAg seroconversion

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; VIRUS DNA;

ACCURACY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD;

ADENINE; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; PHOSPHONIC ACIDS; PROGNOSIS; PYRIMIDINONES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70449367149     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01145.x     Document Type: Article

References (21)

1. Hoofnagle JH, Dusheiko GM, Seeff LB et al. Seroconversion from hepatitis e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981 94 : 744 748.
2. Fattovich G, Rugge M, Brollo L et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986 6 : 167 172.
3. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990 323 : 295 301.
4. Lok ASF, Wu P-C, Lai C-L et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992 102 : 2091 2097.
5. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human interferon in patients with chronic hepatitis B. Gastroenterology 1988 95 : 1318 1325.
6. Chien RN, Liaw YF, Akins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group. Hepatology 1999 30 : 770 774.
7. Yuen MF, Fung SK, Tanaka Y et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004 42 : 5036 5040.
8. Fried MW, Piratvisuth T, Lau GK et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008 47 : 428 434.
9. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002 36 : 186 194.
10. Liu CJ, Chen PJ, Lai MY et al. Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B. Liver Int 2006 26 : 949 955.
11. Lau GK, Piratvisuth T, Luo KX et al., Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352 : 2682 2695.
12. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2005 13 : 881 891.
13. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004 39 : 857 861.
14. Hou J, Yin YK, Xu D et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008 47 : 447 454.
15. Fattovich G, Olivari N, Pasino M et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008 57 : 84 90.
16. Yuan HJ, Ka-Ho Wong D, Doutreloigne J, Sablon E, Lai CL, Yuen MF. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infect 2007 54 : 497 503.
17. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
18. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008 48 : 750 758.
19. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133 : 1437 1444.
20. Liaw YF, Gane E, Leung N et al. 2-year GLOBE trial results: Telbivudine is superior to Lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 136 : 486 495.
21. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008 48 : 335 352.